Holding Drug Companies Accountable
Nussbaum Law Group, P.C. (“NLG”) specializes in class action litigation involving unfair competition, fraud, and off-label marketing in the pharmaceutical industry. Litigation matters involving drug companies often arise at the intersection of intellectual property and antitrust law, presenting especially complex challenges involving U.S. patents and specialized regulatory regimes. The complexity of these actions involve unique challenges and require skilled and focused guidance by experienced practitioners.
With its deep experience in these matters, NLG is widely recognized as one of the nation’s preeminent pharmaceutical litigation firms. The firm’s attorneys have represented classes of direct purchasers as well as large individual corporate clients in pharmaceutical litigation throughout the United States, prosecuting disputes all the way through trial and appeal.
NLG has served as lead counsel in numerous cases involving:
- anticompetitive behavior delaying market entry by generic manufacturers;
- price manipulation and price-fixing cartels;
- inappropriate or misleading off-label promotion of drugs;
- RICO violations.
Over the years, NLG has played a leading role in securing billions of dollars in settlements and verdicts against some of the world’s largest pharmaceutical companies.
Representative Pharmaceutical Class Action Cases
- In re Generic Pharmaceuticals Pricing Antitrust Litigation, 16-md-2724 (E.D. Pa.) (NLG appointed to Direct Purchaser Plaintiff Steering Committee)
- In re Actos Direct Purchaser Antitrust Litigation, 15-cv-03278 (S.D.N.Y.) (NLG appointed Co-Lead Counsel)
- In re Copaxone Antitrust Litigation, 22-cv-1232 (D.N.J) (NLG appointed to Direct Purchaser Plaintiff Executive Committee)
- KPH Healthcare Servs., Inc. v. Mylan N.V., et al., 20-cv-02065 (D. Kan.) (“EpiPen”) (NLG appointed Co-Lead Counsel; settled for over $123 million)
- Meijer, Inc. v. Warner Chilcott Public Limited Company, 12-cv-03824 (E.D. Pa.) (L. Nussbaum appointed Co-Lead Counsel; settled for $15 million)
- Meijer, Inc. v. Braintree Laboratories, Inc., 07-cv-00142 (D. Del.) (L. Nussbaum appointed Co-Lead Counsel; settled for $17.5 million)
- Meijer, Inc. v. Abbott Laboratories, 07-cv-05985 (N.D. Cal.) (L. Nussbaum appointed Co-Lead Counsel; settled for $52 million)
- In re Metoprolol Succinate Direct Purchaser Antitrust Litigation, 06-cv-00052 (D. Del.) (L. Nussbaum appointed Co-Lead Counsel; settled for $20 million)
- In re DDAVP Direct Purchaser Antitrust Litigation, 05-cv-02237 (S.D.N.Y.) (L. Nussbaum appointed Co-Lead Counsel; settled for over $30 million)
- Meijer, Inc. v. Warner Chilcott Holdings Co. III, Ltd., 05-cv-02195 (D.D.C.) (L. Nussbaum appointed Co-Lead Counsel; settled for $22 million)
- In re Children’s Ibuprofen Oral Suspension Antitrust Litigation, 04-mc-00535 (D.D.C.) (L. Nussbaum appointed Lead Counsel; settled for $9.7 million)
- In re Remeron Antitrust Litigation, 03-cv-0085 (D.N.J.) (L. Nussbaum appointed Co-Lead Counsel; settled for $75 million)
- In re Nifedipine Antitrust Litigation, 03-ms-00223 (D.D.C.) (L. Nussbaum appointed Co-Lead Counsel; settled for $35 million)
- Oncology & Radiation Associates, P.A. v. Bristol-Myers Squibb Company & American Bioscience, 01-cv-02313 (D.D.C.) (L. Nussbaum appointed Lead Counsel; settled for $65.8 million)
- In re Relafen Antitrust Litigation, 01-cv-12239 (D. Mass.) (L. Nussbaum appointed Co-Lead Counsel; settled for $175 million)
- In re Lorazepam & Clorazepate Antitrust Litigation, 99-ms-00276 (D.D.C.) (L. Nussbaum appointed Co-Lead Counsel; settled for $37 million)